You are here

  • Home
  • Archive
  • Volume 87, Issue 6
  • Dual chamber pacing in patients with severe heart failure on β blocker and amiodarone treatment: preliminary results of a randomised study

Article Text

Article menu
Download PDFPDF
Scientific letters
Dual chamber pacing in patients with severe heart failure on β blocker and amiodarone treatment: preliminary results of a randomised study
  1. H Nägele,
  2. R Schomburg,
  3. B Petersen,
  4. W Rödiger
  1. Department of Cardiovascular Surgery, University Clinic Eppendorf, Hamburg, Germany
  1. Correspondence to:
    Dr. Herbert Nägele, Klinik für Herz-und Gefäβchirurgie, Universitätsklinikum Hamburg-Eppendorf, Martinistr 52, D-0246 Hamburg, Germany;
    naegele{at}uke.uni-hamburg.de

https://doi.org/10.1136/heart.87.6.566

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Standard dual chamber pacing was first used as adjunctive treatment for severe congestive heart failure in the early 1990s.1 It was proposed that a short atrioventricular delay reduced presystolic mitral regurgitation.2,3 It also may correct chronotropic incompetence and protect against fatal bradyarrhythmias.

    We performed a randomised study to test whether DDDR pacing with optimised atrioventricular (AV) delay and reversal of drug induced bradycardia by rate responsive pacing was beneficial in heart failure patients who were receiving combined treatment with amiodarone and β blockers as empirical prophylaxis against sudden tachyarrhythmic death.4

    In 82 patients with severe heart failure submitted for heart transplantation and without a conventional pacemaker indication between 1996 and 1998 (85% male; 52% idiopathic dilated cardiomyopathy), treatment with low dose amiodarone (1000 mg/week) plus titrated doses of carvedilol (target 50 mg/day) was instituted. In addition, …

    View Full Text